Kazunori Imada

ORCID: 0000-0002-0945-0513 · 5 papers in corpus
article 2025
Novel screening approach for stem cell selective inhibitors and their possible translational therapeutic potential for endometriosis
Reproductive biology ·doi:10.1016/j.repbio.2024.100992

Endometriosis is an estrogen-dependent benign disease characterized by growth of the endometrial tissue outside the uterine wall. Several reports suggest the possibility of the pathogenesis and recurrence of endometriosis being related to f…

article 2014
Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells
The Journal of steroid biochemistry and molecular biology ·doi:10.1016/j.jsbmb.2014.12.008

Dienogest (DNG) is a selective progesterone receptor (PR) agonist and oral administration of DNG is used for the treatment of endometriosis. DNG is considered to act on PR to down-regulate pathophysiological factors associated with endometr…

article 2013
Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β
Fertility and sterility ·doi:10.1016/j.fertnstert.2013.10.038

ObjectiveDienogest (DNG), a selective P receptor (PR) agonist, is used to treat endometriosis. To investigate whether DNG affects nerve growth factor (NGF) expression, we stimulated human endometrial epithelial cells (hEECs) with inflammato…

article 2011
Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells
·doi:10.1016/j.fertnstert.2011.09.040

ObjectiveTo investigate the effect of dienogest on the expression of Toll-like receptor (TLR) 4 in human endometrial epithelial cells.DesignProspective basic research study.SettingPharmaceutical research center.Patient(s)None.Intervention(s…

article 2007
Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile
·doi:10.1016/j.steroids.2007.10.003

Dienogest was introduced as an oral progestin. Yet its strong oral potency on endometrial activity is not clearly explained. To circumvent this situation, steroid hormone receptor profiling using transactivation assay and endometrial activi…